Hepatitis e infection in liver transplant recipients

Alberto Unzueta, Jorge Rakela

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hepatitis E virus (HEV) infection (genotype 3) has been described in developed countries as a cause of chronic hepatitis in recipients of solid organ transplantation (SOT), with the first cases reported in 2008. Immunosuppression seems to play a major role in the pathogenesis of chronic infections. The current gold standard for the diagnosis of HEV infection is the detection of HEV RNA in serum, stools, or both. In liver transplant recipients, HEV infection is considered an uncommon disease; however, a high index of suspicion is needed for patients with graft hepatitis of an unclear etiology. Liver transplant recipients seem more likely to develop chronic HEV after an acute infection, and there is accelerated progression to advanced fibrosis and cirrhosis. A decrease in immunosuppression is considered the first line of treatment, and pegylated interferon can be considered the second line of treatment for liver transplant recipients. At the present time, there are not enough data to recommend treatment with ribavirin for adult liver transplant recipients, although this has been tried in other SOT populations. Liver Transpl 20:15-24, 2014.

Original languageEnglish (US)
Pages (from-to)15-24
Number of pages10
JournalLiver Transplantation
Volume20
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Hepatitis E virus
Hepatitis
Virus Diseases
Liver
Infection
Organ Transplantation
Chronic Hepatitis
Immunosuppression
Fibrosis
Ribavirin
Developed Countries
Interferons
Therapeutics
Genotype
Transplant Recipients
RNA
Transplants
Serum
Population

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Hepatitis e infection in liver transplant recipients. / Unzueta, Alberto; Rakela, Jorge.

In: Liver Transplantation, Vol. 20, No. 1, 2014, p. 15-24.

Research output: Contribution to journalArticle

Unzueta, Alberto ; Rakela, Jorge. / Hepatitis e infection in liver transplant recipients. In: Liver Transplantation. 2014 ; Vol. 20, No. 1. pp. 15-24.
@article{85a8fe8a73a0463faa9b59c774eb99aa,
title = "Hepatitis e infection in liver transplant recipients",
abstract = "Hepatitis E virus (HEV) infection (genotype 3) has been described in developed countries as a cause of chronic hepatitis in recipients of solid organ transplantation (SOT), with the first cases reported in 2008. Immunosuppression seems to play a major role in the pathogenesis of chronic infections. The current gold standard for the diagnosis of HEV infection is the detection of HEV RNA in serum, stools, or both. In liver transplant recipients, HEV infection is considered an uncommon disease; however, a high index of suspicion is needed for patients with graft hepatitis of an unclear etiology. Liver transplant recipients seem more likely to develop chronic HEV after an acute infection, and there is accelerated progression to advanced fibrosis and cirrhosis. A decrease in immunosuppression is considered the first line of treatment, and pegylated interferon can be considered the second line of treatment for liver transplant recipients. At the present time, there are not enough data to recommend treatment with ribavirin for adult liver transplant recipients, although this has been tried in other SOT populations. Liver Transpl 20:15-24, 2014.",
author = "Alberto Unzueta and Jorge Rakela",
year = "2014",
doi = "10.1002/lt.23764",
language = "English (US)",
volume = "20",
pages = "15--24",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Hepatitis e infection in liver transplant recipients

AU - Unzueta, Alberto

AU - Rakela, Jorge

PY - 2014

Y1 - 2014

N2 - Hepatitis E virus (HEV) infection (genotype 3) has been described in developed countries as a cause of chronic hepatitis in recipients of solid organ transplantation (SOT), with the first cases reported in 2008. Immunosuppression seems to play a major role in the pathogenesis of chronic infections. The current gold standard for the diagnosis of HEV infection is the detection of HEV RNA in serum, stools, or both. In liver transplant recipients, HEV infection is considered an uncommon disease; however, a high index of suspicion is needed for patients with graft hepatitis of an unclear etiology. Liver transplant recipients seem more likely to develop chronic HEV after an acute infection, and there is accelerated progression to advanced fibrosis and cirrhosis. A decrease in immunosuppression is considered the first line of treatment, and pegylated interferon can be considered the second line of treatment for liver transplant recipients. At the present time, there are not enough data to recommend treatment with ribavirin for adult liver transplant recipients, although this has been tried in other SOT populations. Liver Transpl 20:15-24, 2014.

AB - Hepatitis E virus (HEV) infection (genotype 3) has been described in developed countries as a cause of chronic hepatitis in recipients of solid organ transplantation (SOT), with the first cases reported in 2008. Immunosuppression seems to play a major role in the pathogenesis of chronic infections. The current gold standard for the diagnosis of HEV infection is the detection of HEV RNA in serum, stools, or both. In liver transplant recipients, HEV infection is considered an uncommon disease; however, a high index of suspicion is needed for patients with graft hepatitis of an unclear etiology. Liver transplant recipients seem more likely to develop chronic HEV after an acute infection, and there is accelerated progression to advanced fibrosis and cirrhosis. A decrease in immunosuppression is considered the first line of treatment, and pegylated interferon can be considered the second line of treatment for liver transplant recipients. At the present time, there are not enough data to recommend treatment with ribavirin for adult liver transplant recipients, although this has been tried in other SOT populations. Liver Transpl 20:15-24, 2014.

UR - http://www.scopus.com/inward/record.url?scp=84896547450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896547450&partnerID=8YFLogxK

U2 - 10.1002/lt.23764

DO - 10.1002/lt.23764

M3 - Article

C2 - 24123928

AN - SCOPUS:84896547450

VL - 20

SP - 15

EP - 24

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 1

ER -